← Eichor
Study identifier: NCT07238868 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy

Condition: Focal Epilepsy  ·  Sponsor: Shanghai Zhimeng Biopharma, Inc.

PhasePhase 2
Planned participants144
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

This description comes directly from the study's public registry record.

Talk to the study team

Terence O'Brien, professor  ·  0390762029  ·  te.obrien@alfred.org.au

Always discuss trial participation with your own doctor first.

Locations (1)

Alfred HealthMelbourne, Victoria, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07238868